AUSTRALIA Trends and Developments Contributed by: Suzy Madar, Matthew Swinn, Kate Hay and Scott Bouvier, Mallesons
For 2026 and 2027, the TGA’s priority areas for enforcement will be direct-to-consumer IVD kits, erec- tile dysfunction and weight loss medications, foetal dopplers, advertising of listed medicines, melatonin and medicinal cannabis, sunscreens and cosmetic procedures that involve therapeutic goods. Vaping products also remain on the list of priorities. While AI-specific regulation remains fragmented, the TGA is actively examining issues relating to model validation, bias, explainability and human oversight, particularly where automated outputs influence diag- nosis, triage or treatment decisions. Products trained on overseas datasets or continuous learning systems present heightened regulatory sensitivity. In practice, sponsors should expect to justify how AI tools perform in Australian clinical contexts and how responsibility for decision-making is allocated between technology and clinicians. As boundaries are increasingly blurred between phar- maceuticals, medical devices and consumer goods, the TGA will be closely scrutinising whether products have been appropriately classified. Misclassification risk is now a leading enforcement consideration given the severe downstream consequences that may flow from conformity assessment, evidence thresholds and post-market obligations. For sponsors and manufac- turers, early classification decisions are important and should be pressure-tested well before launch. The TGA recently passed a raft of reforms to the classifi- cation of selected medical devices, with transitional arrangements currently in place until 1 July 2029. Priority focus areas for the TGA signal where scrutiny is most likely to be concentrated in the near term. However, the framework is deliberately agile, allowing enforcement activity to extend beyond listed priorities where emerging risks arise. At a macro level, the TGA is placing greater emphasis on post-market surveil- lance and life cycle compliance, requiring sponsors to have effective systems in place to detect, investigate and respond to safety signals once products are in use. This is particularly relevant for advanced biologi- cals, personalised medicines and SaMD, where risks may only emerge at scale over time. Importantly, reg- ulator expectations are extending beyond traditional recalls to encompass software updates, algorithm
changes and data-driven modifications. Sponsors should assume that ongoing change management, documentation and validation will be scrutinised as part of routine compliance activity. The TGA is also operating in closer alignment with consumer protection and health practitioner regula- tion. Claims made in marketing, digital interfaces and patient-facing apps are increasingly assessed through both therapeutic goods and Australian Consumer Law lenses, particularly where efficacy, safety or price representations are concerned. Enforcement trends also point to greater scrutiny of comparative claims in health-adjacent markets. Looking Ahead: Proving Value in an Era of Accountability Stepping back, the defining feature of Australia’s life sciences landscape in 2026 is not the pace of innova- tion but the growing expectation that innovation must be durable, defensible and accountable across its full life cycle. As products and services scale more quick- ly, operate across multiple care settings, and inter- act with increasingly complex regulatory and funding frameworks, legal risk is less likely to arise at the point of approval and more at moments of transition – from pilot to scale, from specialist to community use, and from early promise to long-term reliance. For industry participants, this shift places a premium on foresight. Decisions about evidence generation, gov- ernance, data use, commercial structure and allocation of responsibility are no longer peripheral considera- tions but are central to long-term value and resilience. Regulators, funders, investors and the community are increasingly aligned in expecting not just compliance with minimum standards but also demonstrable man - agement of risk, trust and public resources. In this environment, success will be achieved by organisations that treat legal and regulatory strategy as an enabling architecture rather than a constraint – embedded early, revisited often and capable of evolv- ing as technologies, markets and societal expecta- tions continue to change.
30 CHAMBERS.COM
Powered by FlippingBook